Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

As the pharmaceutical industry continues to push the boundaries of innovation, the role of digital solutions like eCOA platforms will only grow in significance. For rare disease trials, where patient ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...

Alzheon has been left sifting through the data of a failed Alzheimer's disease trial for crumbs of evidence that its oral therapy may have some efficacy. The top-line results of the APOLLOE4 trial ...

The UK government has said it will invest up to £600 million ($764 million) in the creation of a centralised health data platform, creating a single point of contact for medical researchers ...

For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access insights report from EVERSANA (pharmaphorum's parent company). You can see the ...